Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liothyronine + methimazole
- Development stage
- Discontinued
- Lead developer
- ITL Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Liothyronine + methimazole** is a combination of two pharmaceuticals with directly opposing effects on thyroid hormone metabolism. **Liothyronine** is a synthetic form of the active thyroid hormone triiodothyronine (T3), acting as a thyroid hormone receptor agonist to increase metabolic rate and compensate for hypothyroidism. **Methimazole** is an antithyroid thionamide that inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones and used to treat hyperthyroidism. The combination is not commonly used in clinical practice and is generally advised against due to antagonistic pharmacological actions, unless specifically indicated in rare specialist protocols, as their effects counteract each other. No marketed fixed-dose combination product using both substances was identified.
- Brand names
- TapazoleNorthyx
- Other names
- triiodothyronineT3T-3T 3
02
Targets
THRB (Thyroid hormone receptor beta)TPO (Thyroid peroxidase)THRA (Thyroid hormone receptor alpha)
Beyond the preview
Go deeper on liothyronine + methimazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liothyronine + methimazole.